Premium
Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis
Author(s) -
Tsirigotis Panagiotis,
Vassilakopoulos Theodoros,
Batsis Ioannis,
Bousiou Zoi,
Gkirkas Konstantinos,
Sakellari Ioanna,
Kaloyannidis Panayotis,
Roussou Paraskevi,
Pangalis Gerassimos A.,
Moschogiannis Maria,
Vassilopoulos George,
Repousis Panagiotis,
Megalakaki Aekaterini,
Michalis Eurydiki,
Kalpadakis Christina,
Papadaki Helen A.,
Kotsianidis Ioannis,
Hatzimichael Eleftheria,
Spyridonidis Alexandros,
Anargyrou Konstantinos,
Poulakidas Elias,
Giannoullia Panagiota,
Apostolidis Ioannis,
Stamouli Maria,
Konstantopoulos Konstantinos,
Pappa Vassiliki,
Panayiotidis Panayiotis,
Harhalakis Nikolaos,
Anagnostopoulos Achilles,
Angelopoulou Maria
Publication year - 2018
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2521
Subject(s) - brentuximab vedotin , medicine , oncology , autologous stem cell transplantation , transplantation , classical hodgkin lymphoma , lymphoma , cd30 , stem cell , hodgkin lymphoma , biology , genetics
The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto‐SCT) is poor. Recently, the anti‐CD30 monoclonal antibody‐drug conjugate, brentuximab vedotin (BV), has shown remarkable activity in the setting of R/R cHL. In the pivotal phase II study, BV produced an overall response rate of 75% and a median progression‐free survival of 6.7 months. Although these results have been reproduced by large registry studies, the impact of BV on the overall survival (OS) of patients with R/R cHL has not been addressed so far. The aim of this study was to examine the impact of BV on OS in the setting of post auto‐SCT R/R cHL. Analysis was performed in a group of patients with R/R cHL after a previous auto‐SCT reported in the Greek registry during the last 2 decades. By using a multivariate model and censoring patients at the time of subsequent allo‐SCT or treatment with immune checkpoint inhibitors, we showed that treatment with BV in the posttransplant relapse setting has a positive impact on the outcome and results in significant improvement of OS. To our knowledge, this the first published study, addressing the impact of BV on the OS in the setting of posttransplant relapse.